NNNN (Anbio Biotechnology) PE Ratio without NRI: 92.30 (As of Jul. 04, 2026) — 54% Below Median


NNNN Anbio Biotechnology NNNN
24 GF Score
Price $12.46
! 2 Warning Signs
View Full Analysis

What is Anbio Biotechnology PE Ratio without NRI?

Anbio Biotechnology NNNN +2.88% 24 PE Ratio without NRI is 92.30 as of Jul. 04, 2026, which is 54% below its 10-year median of 200.37. GuruFocus rates NNNN with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 446 Medical Devices & Instruments companies, Anbio Biotechnology ranks worse than 90.81% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-04), Anbio Biotechnology's share price is $12.46. Anbio Biotechnology's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $0.14. Therefore, Anbio Biotechnology's PE Ratio without NRI for today is 92.30.

During the past 5 years, Anbio Biotechnology's highest PE Ratio without NRI was 945.56. The lowest was 92.30. And the median was 200.37.

Anbio Biotechnology's EPS without NRI for the six months ended in Dec. 2025 was $0.06. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $0.14.

As of today (2026-07-04), Anbio Biotechnology's share price is $12.46. Anbio Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.15. Therefore, Anbio Biotechnology's PE Ratio (TTM) for today is 84.76.

Good Sign:

Anbio Biotechnology stock PE Ratio (=84.76) is close to 2-year low of 84.76.

During the past years, Anbio Biotechnology's highest PE Ratio (TTM) was 945.56. The lowest was 84.76. And the median was 185.37.

Anbio Biotechnology's EPS (Diluted) for the six months ended in Dec. 2025 was $0.06. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.15.

Anbio Biotechnology's EPS (Basic) for the six months ended in Dec. 2025 was $0.06. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.15.


Anbio Biotechnology  (NAS:NNNN) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Anbio Biotechnology PE Ratio without NRI Related Terms


Anbio Biotechnology PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for Anbio Biotechnology's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anbio Biotechnology PE Ratio without NRI Chart

Anbio Biotechnology Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio without NRI
N/A N/A N/A N/A 221.10

Anbio Biotechnology Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only N/A N/A N/A At Loss 221.10

NNNN vs ANGO, OSUR, UTMD: PE Ratio without NRI Comparison

For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anbio Biotechnology PE Ratio without NRI vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Anbio Biotechnology's PE Ratio without NRI falls into.


NNNN
24GF Score
Anbio Biotechnology NNNN
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anbio Biotechnology PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Anbio Biotechnology's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=12.46/0.135
=92.3

Anbio Biotechnology's Share Price of today is $12.46.
For company reported semi-annually, Anbio Biotechnology's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.14.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 92.30 mean?
Anbio Biotechnology (NNNN) has a PE Ratio without NRI of 92.30 as of Jul. 04, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Anbio Biotechnology and its competitors. This is 54% below median its historical median of 200.37. Over the past decade, Anbio Biotechnology's PE Ratio without NRI has ranged from 92.30 to 945.56. According to the industry distribution chart, Anbio Biotechnology ranks #405 out of 446 companies in the Medical Devices & Instruments industry, placing it in the top 90.8%.
Is Anbio Biotechnology's PE Ratio without NRI too high?
Anbio Biotechnology's current PE Ratio without NRI of 92.30 is 54% below median its 10-year median of 200.37. Over the past 10 years, this metric has ranged from a low of 92.30 to a high of 945.56. The Medical Devices & Instruments industry median PE Ratio without NRI is 23.91. Anbio Biotechnology's value of 92.30 is 286% above this industry median. Based on the distribution chart, Anbio Biotechnology ranks #405 out of 446 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's PE Ratio without NRI compare to ANGO and OSUR?
According to the Medical Devices & Instruments industry distribution chart, Anbio Biotechnology ranks #405 out of 446 companies for PE Ratio without NRI. This places Anbio Biotechnology in the lower half of its industry. The industry median PE Ratio without NRI is 23.91. Anbio Biotechnology's value of 92.30 is 286% above this benchmark. Historically, Anbio Biotechnology's own PE Ratio without NRI has ranged from 92.30 to 945.56 over the past decade. While the company's 10-year median is 200.37 vs. the industry median of 23.91, Anbio Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Medical Devices & Instruments company?
The median PE Ratio without NRI among Medical Devices & Instruments companies is 23.91, based on 446 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anbio Biotechnology's current PE Ratio without NRI of 92.30 is 286% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Anbio Biotechnology and its competitors. For the Medical Devices & Instruments industry, the median PE Ratio without NRI is 23.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anbio Biotechnology's current PE Ratio without NRI is 92.30, which is 54% below median its own 10-year median of 200.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current PE Ratio without NRI of 92.30. The current PE Ratio without NRI is 92.30, which is 54% below median its 10-year median of 200.37 and 286% above the Medical Devices & Instruments industry median of 23.91. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current PE Ratio without NRI is 92.30 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anbio Biotechnology Business Description

Address Friedrich-Ebert-Anlage 35-37, Frankfurt am Main, HE, DEU, 60327
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score

Get the complete analysis for NNNN

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.46
Price